TAG HIV Basic Science, Vaccines, and Cure Project Blog
By Richard Jefferys, Project Director at Treatment Action Group (TAG).
recent posts
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the February 2026 Update
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the December 2025 and January 2026 Updates
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the November 2025 Update
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the October 2025 Update
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the September 2025 Update
Category: CD4/CD8 ratio
-
There are twelve updates to the listing this month: four new interventional trials and one observational study have been added (all yet to start recruiting), a planned observational study was withdrawn, a trial of immunomodulators has begun recruiting in China, one trial has shifted to the completed studies table, and links to presentations/publications describing results…
-
Since posting recently about studies investigating the relevance of the CD4/CD8 ratio in the antiretroviral therapy era, several new papers and presentations have provided more information on the topic. Last week in the open access journal PLoS Pathogens, Sergio Serrano-Villar and colleagues reported evidence that a low CD4/CD8 ratio (less than or equal to 0.4)—despite…
-
An inversion of the normal ratio between CD4 and CD8 T cells was noted in the very first case reports of individuals with AIDS, before HIV was even identified. Although a number of studies subsequently reported an association between the CD4/CD8 ratio and risk of disease progression, CD4 T cell counts were more extensively researched…